{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:26:50Z","timestamp":1792452410405,"version":"4.5.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1038\/s41401-025-01713-5","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T09:41:16Z","timestamp":1768556476000},"page":"1285-1299","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Discovery of a potent and orally bioavailable type \u2160 PRMTs inhibitor for triple-negative breast cancer treatment"],"prefix":"10.1038","volume":"47","author":[{"given":"Shu-yan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang-sheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-hao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan-zhan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-quan","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luo-ting","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"1713_CR1","unstructured":"World Health Organization. Breast cancer [Fact sheet on the Internet]. Geneva: World Health Organization; c2025 [updated 2025 August 14; cited 2025 Sep 30]. Available from: https:\/\/www.who.int\/zh\/news-room\/fact-sheets\/detail\/breast-cancer."},{"key":"1713_CR2","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","volume":"391","author":"P Schmid","year":"2024","unstructured":"Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, K\u00fcmmel S, et al. Overall survival with Pembrolizumab in early-stage triple-negative breast cancer. N Engl J Med. 2024;391:1981\u201391.","journal-title":"N Engl J Med"},{"key":"1713_CR3","doi-asserted-by":"publisher","first-page":"e2461639","DOI":"10.1001\/jamanetworkopen.2024.61639","volume":"8","author":"L Richters","year":"2025","unstructured":"Richters L, Gluz O, Weber-Lassalle N, Christgen M, Haverkamp H, Kuemmel S, et al. Genetic alterations, therapy response, and survival among patients with triple-negative breast cancer. JAMA Netw Open. 2025;8:e2461639.","journal-title":"JAMA Netw Open"},{"key":"1713_CR4","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.cell.2023.01.040","volume":"186","author":"E Nolan","year":"2023","unstructured":"Nolan E, Lindeman GJ, Visvader JE. Deciphering breast cancer: from biology to the clinic. Cell. 2023;186:1708\u201328.","journal-title":"Cell"},{"key":"1713_CR5","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s43018-023-00535-w","volume":"4","author":"XX Sun","year":"2023","unstructured":"Sun XX, Tang HY, Chen Y, Chen ZX, Hu ZY, Cui Z, et al. Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer. Nat Cancer. 2023;4:716\u201333.","journal-title":"Nat Cancer"},{"key":"1713_CR6","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung HYA, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"1713_CR7","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3390\/cancers11040559","volume":"11","author":"N Khaled","year":"2019","unstructured":"Khaled N, Bidet Y. New insights into the implication of epigenetic alterations in the EMT of triple negative breast cancer. Cancers. 2019;11:559.","journal-title":"Cancers"},{"key":"1713_CR8","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.semcancer.2020.05.010","volume":"72","author":"KK Wong","year":"2021","unstructured":"Wong KK. DNMT1: A key drug target in triple-negative breast cancer. Semin Cancer Biol. 2021;72:198\u2013213.","journal-title":"Semin Cancer Biol"},{"key":"1713_CR9","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/s41586-024-08031-6","volume":"635","author":"AE Schade","year":"2024","unstructured":"Schade AE, Perurena N, Yang Y, Rodriguez CL, Krishnan A, Gardner A, et al. AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution. Nature. 2024;635:755\u201363.","journal-title":"Nature"},{"key":"1713_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04381-5","volume":"12","author":"ZW Li","year":"2021","unstructured":"Li ZW, Wang DD, Chen XT, Wang WW, Wang PF, Hou PF, et al. PRMT1-mediated EZH2 methylation promotes breast cancer cell proliferation and tumorigenesis. Cell Death Dis. 2021;12:1080.","journal-title":"Cell Death Dis"},{"key":"1713_CR11","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2023.2196482","volume":"28","author":"MZM Jiffry","year":"2023","unstructured":"Jiffry MZM, Kloss R, Ahmed-khan M, Carmona-Pires F, Okam N, Weeraddana P, et al. A review of treatment options employed in relapsed\/refractory AML. Hematology. 2023;28:2196482.","journal-title":"Hematology"},{"key":"1713_CR12","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.molmed.2019.05.007","volume":"25","author":"J Jarrold","year":"2019","unstructured":"Jarrold J, Davies CC. PRMTs and arginine methylation: cancer\u2019s best-kept secret? Trends Mol Med. 2019;25:993\u20131009.","journal-title":"Trends Mol Med"},{"key":"1713_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.101016","volume":"72","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Xia T, Chen D-Q, Xiong X, Shi L, Zuo Y, et al. Promising role of protein arginine methyltransferases in overcoming anti-cancer drug resistance. Drug Resist Updat. 2024;72:101016.","journal-title":"Drug Resist Updat"},{"key":"1713_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122538","volume":"342","author":"SY Zhou","year":"2024","unstructured":"Zhou SY, Zhang QS, Yang HL, Zhu YX, Hu X, Wan GQ, et al. Targeting type I PRMTs as promising targets for the treatment of pulmonary disorders: asthma, COPD, lung cancer, PF, and PH. Life Sci. 2024;342:122538.","journal-title":"Life Sci"},{"key":"1713_CR15","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1158\/0008-5472.CAN-18-3211","volume":"79","author":"LM Liu","year":"2019","unstructured":"Liu LM, Sun WZ, Fan XZ, Xu YL, Cheng MB, Zhang Y. Methylation of C\/EBP\u03b1 by PRMT1 inhibits its iumor-suppressive function in breast cancer. Cancer Res. 2019;79:2865\u201377.","journal-title":"Cancer Res"},{"key":"1713_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1158\/0008-5472.CAN-18-1995","volume":"79","author":"JQ Bao","year":"2018","unstructured":"Bao JQ, Di Lorenzo A, Lin K, Lu Y, Zhong Y, Sebastian MM, et al. Mouse models of overexpression reveal distinct oncogenic roles for different type I protein arginine methyltransferases. Cancer Res. 2018;79:21\u201332.","journal-title":"Cancer Res"},{"key":"1713_CR17","doi-asserted-by":"publisher","first-page":"306","DOI":"10.3390\/cancers14020306","volume":"14","author":"S Suresh","year":"2021","unstructured":"Suresh S, Huard S, Brisson A, N\u00e9mati F, Poulard C, Ye M, et al. PRMT1 regulates EGFR and Wnt signaling pathways and is a promising target for combinatorial treatment of breast cancer. Cancers. 2021;14:306.","journal-title":"Cancers"},{"key":"1713_CR18","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1038\/s41418-020-00615-9","volume":"27","author":"ZW Li","year":"2020","unstructured":"Li ZW, Wang DD, Lu J, Huang BQ, Wang YB, Dong MC, et al. Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis. Cell Death Differ. 2020;27:3226\u2013342.","journal-title":"Cell Death Differ"},{"key":"1713_CR19","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201948597","volume":"21","author":"JW Liu","year":"2019","unstructured":"Liu JW, Feng JX, Li LL, Lin LY, Ji JF, Lin C, et al. Arginine methylation-dependent LSD1 stability promotes invasion and metastasis of breast cancer. EMBO Rep. 2019;21:e48597.","journal-title":"EMBO Rep"},{"key":"1713_CR20","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41573-021-00159-8","volume":"20","author":"Q Wu","year":"2021","unstructured":"Wu Q, Schapira M, Arrowsmith CH, Barsyte-Lovejoy D. Protein arginine methylation: from enigmatic functions to therapeutic targeting. Nat Rev Drug Discov. 2021;20:509\u201330.","journal-title":"Nat Rev Drug Discov"},{"key":"1713_CR21","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/cr.2011.128","volume":"22","author":"ZB Yu","year":"2012","unstructured":"Yu ZB, Vogel G, Coulombe Y, Dubeau D, Spehalski E, H\u00e9bert J, et al. The MRE11 GAR motif regulates DNA double-strand break processing and ATR activation. Cell Res. 2012;22:305\u201320.","journal-title":"Cell Res"},{"key":"1713_CR22","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.3390\/jpm11101009","volume":"11","author":"WJ Hsu","year":"2021","unstructured":"Hsu WJ, Chen CH, Chang YC, Cheng CH, TsaI YH, Lin CW. PRMT1 confers resistance to olaparib via modulating MYC signaling in triple-negative breast cancer. J Pers Med. 2021;11:1009.","journal-title":"J Pers Med"},{"key":"1713_CR23","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3390\/life11080789","volume":"11","author":"LM Liu","year":"2021","unstructured":"Liu LM, Tang Q, Hu X, Zhao JJ, Zhang Y, Ying GG, et al. Arginine methyltransferase PRMT1 regulates p53 activity in breast cancer. Life. 2021;11:789.","journal-title":"Life"},{"key":"1713_CR24","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/s41589-022-01024-4","volume":"18","author":"Q Wu","year":"2022","unstructured":"Wu Q, Nie DY, Ba-alawi W, Ji YS, Zhang ZW, Cruickshank J, et al. PRMT inhibition induces a viral mimicry response in triple-negative breast cancer. Nat Chem Biol. 2022;18:821\u201330.","journal-title":"Nat Chem Biol"},{"key":"1713_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101326","volume":"4","author":"Y Li","year":"2023","unstructured":"Li Y, Dobrolecki LE, Sallas C, Zhang X, Kerr TD, Bisht D, et al. PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition. Cell Rep Med. 2023;4:101326.","journal-title":"Cell Rep Med"},{"key":"1713_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01037-1","volume":"13","author":"C Dominici","year":"2021","unstructured":"Dominici C, Sgarioto N, Yu ZB, Sesma-Sanz L, Masson JY, Richard S, et al. Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells. Clin Epigenetics. 2021;13:54.","journal-title":"Clin Epigenetics"},{"key":"1713_CR27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ccell.2019.05.014","volume":"36","author":"A Fedoriw","year":"2019","unstructured":"Fedoriw A, Rajapurkar SR, O\u2019Brien S, Gerhart SV, Mitchell LH, Adams ND, et al. Anti-tumor activity of the type i PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss. Cancer Cell. 2019;36:100\u2013114.e25.","journal-title":"Cancer Cell"},{"key":"1713_CR28","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1021\/acschembio.5b00839","volume":"11","author":"MS Eram","year":"2016","unstructured":"Eram MS, Shen YD, Szewczyk MM, Wu H, Senisterra G, Li FL, et al. A potent, selective, and cell-active inhibitor of human type I protein arginine methyltransferases. ACS Chem Biol. 2016;11:772\u201381.","journal-title":"ACS Chem Biol"},{"key":"1713_CR29","doi-asserted-by":"publisher","first-page":"4893","DOI":"10.1016\/j.apsb.2023.07.022","volume":"13","author":"YC Deng","year":"2023","unstructured":"Deng YC, Song XS, Iyamu ID, Dong AP, Min JR, Huang R. A unique binding pocket induced by a noncanonical SAH mimic to develop potent and selective PRMT inhibitors. Acta Pharm Sin B. 2023;13:4893\u2013905.","journal-title":"Acta Pharm Sin B"},{"key":"1713_CR30","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7086390","volume":"2016","author":"F Ye","year":"2016","unstructured":"Ye F, Zhang W, Lu W, Xie Y, Jiang H, Jin J, et al. Identification of novel inhibitors against coactivator associated arginine methyltransferase 1 based on virtual screening and biological assays. Biomed Res Int. 2016;2016:7086390.","journal-title":"Biomed Res Int"},{"key":"1713_CR31","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1021\/jm401884z","volume":"57","author":"LL Yan","year":"2014","unstructured":"Yan LL, Yan CL, Qian K, Su HR, Kofsky-Wofford SA, Lee WC, et al. Diamidine compounds for selective inhibition of protein arginine methyltransferase 1. J Med Chem. 2014;57:2611\u201322.","journal-title":"J Med Chem"},{"key":"1713_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113385","volume":"42","author":"WJ Li","year":"2023","unstructured":"Li WJ, Huang Y, Lin YA, Zhang BD, Li MY, Zou YQ, et al. Targeting PRMT1-mediated SRSF1 methylation to suppress oncogenic exon inclusion events and breast tumorigenesis. Cell Rep. 2023;42:113385.","journal-title":"Cell Rep"},{"key":"1713_CR33","doi-asserted-by":"publisher","first-page":"5166","DOI":"10.1002\/anie.201412154","volume":"54","author":"H\u00dc Kaniskan","year":"2015","unstructured":"Kaniskan H\u00dc, Szewczyk MM, Yu ZT, Eram MS, Yang XB, Schmidt K, et al. A potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3). Angew Chem Int Ed Engl. 2015;54:5166\u201370.","journal-title":"Angew Chem Int Ed Engl"},{"key":"1713_CR34","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1021\/acs.jcim.1c01100","volume":"62","author":"X Li","year":"2022","unstructured":"Li X, Zhang L, Xu J, Liu CY, Zhang XJ, Abdelmoneim AA, et al. Identification, synthesis, and biological evaluations of potent inhibitors targeting type I protein arginine methyltransferases. J Chem Inf Model. 2022;62:692\u2013702.","journal-title":"J Chem Inf Model"},{"key":"1713_CR35","doi-asserted-by":"publisher","first-page":"6838","DOI":"10.1021\/acs.jmedchem.6b00668","volume":"59","author":"R Ferreira de Freitas","year":"2016","unstructured":"Ferreira de Freitas R, Eram MS, Smil D, Szewczyk MM, Kennedy S, Brown PJ, et al. Discovery of a potent and selective coactivator associated arginine methyltransferase 1 (CARM1) inhibitor by virtual screening. J Med Chem. 2016;59:6838\u201347.","journal-title":"J Med Chem"},{"key":"1713_CR36","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.1021\/acs.jmedchem.0c00406","volume":"63","author":"YD Shen","year":"2020","unstructured":"Shen YD, Li FL, Szewczyk MM, Halabelian L, Park KS, Chau I, et al. Discovery of a first-in-class protein arginine methyltransferase 6 (PRMT6) covalent inhibitor. J Med Chem. 2020;63:5477\u201387.","journal-title":"J Med Chem"},{"key":"1713_CR37","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1021\/acsmedchemlett.5b00071","volume":"6","author":"LH Mitchell","year":"2015","unstructured":"Mitchell LH, Drew AE, Ribich SA, Rioux N, Swinger KK, Jacques SL, et al. Aryl pyrazoles as potent inhibitors of arginine methyltransferases: identification of the first PRMT6 tool compound. ACS Med Chem Lett. 2015;6:655\u20139.","journal-title":"ACS Med Chem Lett"},{"key":"1713_CR38","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.str.2012.06.001","volume":"20","author":"A Siarheyeva","year":"2012","unstructured":"Siarheyeva A, Senisterra G, Allali-Hassani A, Dong AP, Dobrovetsky E, Wasney GA, et al. An allosteric inhibitor of protein arginine methyltransferase 3. Structure. 2012;20:1425\u201335.","journal-title":"Structure"},{"key":"1713_CR39","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1021\/jm3018332","volume":"56","author":"F Liu","year":"2013","unstructured":"Liu F, Li FL, Ma AQ, Dobrovetsky E, Dong AP, Gao C, et al. Exploiting an allosteric binding site of PRMT3 yields potent and selective inhibitors. J Med Chem. 2013;56:2110\u201324.","journal-title":"J Med Chem"},{"key":"1713_CR40","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1021\/acs.jmedchem.7b01674","volume":"61","author":"H\u00dc Kaniskan","year":"2018","unstructured":"Kaniskan H\u00dc, Eram MS, Zhao K, Szewczyk MM, Yang X, Schmidt K, et al. Discovery of potent and selective allosteric Inhibitors of arotein arginine aethyltransferase 3 (PRMT3). J Med Chem. 2018;61:1204\u201317.","journal-title":"J Med Chem"},{"key":"1713_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116212","volume":"267","author":"C Tong","year":"2024","unstructured":"Tong C, Chang XJ, Qu FG, Bian JL, Wang JB, Li ZY, et al. Overview of the development of protein arginine methyltransferase modulators: achievements and future directions. Eur J Med Chem. 2024;267:116212.","journal-title":"Eur J Med Chem"},{"key":"1713_CR42","doi-asserted-by":"publisher","first-page":"6279","DOI":"10.1158\/1538-7445.AM2023-6279","volume":"83","author":"H Shi","year":"2023","unstructured":"Shi H, Fu XN, Ouyang QG, Huang JX, Wang YQ, Wang YZ, et al. Abstract 6279: CTS2190, a next-generation epigenetic inhibitor for targeting type I PRMT deregulated human tumors. Cancer Res. 2023;83:6279.","journal-title":"Cancer Res"},{"key":"1713_CR43","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41416-023-02276-0","volume":"129","author":"AB El-Khoueiry","year":"2023","unstructured":"El-Khoueiry AB, Clarke J, Neff T, Crossman T, Ratia N, Rathi C, et al. Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors. Br J Cancer. 2023;129:309\u201317.","journal-title":"Br J Cancer"},{"key":"1713_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2020.112152","volume":"394","author":"GH Hu","year":"2020","unstructured":"Hu GH, Yan C, Xie PY, Cao Y, Shao J, Ge J. PRMT2 accelerates tumorigenesis of hepatocellular carcinoma by activating Bcl2 via histone H3R8 methylation. Exp Cell Res. 2020;394:112152.","journal-title":"Exp Cell Res"},{"key":"1713_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100821","volume":"297","author":"T Cai","year":"2021","unstructured":"Cai T, Yu ZB, Wang Z, Liang C, Richard S. Arginine methylation of SARS-Cov-2 nucleocapsid protein regulates RNA binding, its ability to suppress stress granule formation, and viral replication. J Biol Chem. 2021;297:100821.","journal-title":"J Biol Chem"},{"key":"1713_CR46","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/j.apsb.2021.10.016","volume":"12","author":"ZW Zhang","year":"2022","unstructured":"Zhang ZW, Ding SL, Wang Z, Zhu XW, Zhou ZL, Zhang WW, et al. Prmt1 upregulated by Hdc deficiency aggravates acute myocardial infarction via NETosis. Acta Pharm Sin B. 2022;12:1840\u201355.","journal-title":"Acta Pharm Sin B"},{"key":"1713_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-77028-8","volume":"10","author":"A Plotnikov","year":"2020","unstructured":"Plotnikov A, Kozer N, Cohen G, Carvalho S, Duberstein S, Almog O, et al. PRMT1 inhibition induces differentiation of colon cancer cells. Sci Rep. 2020;10:20030.","journal-title":"Sci Rep"},{"key":"1713_CR48","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1016\/j.chembiol.2024.08.003","volume":"31","author":"KJ Zhang","year":"2024","unstructured":"Zhang KJ, Wei J, Zhang SY, Fei LY, Guo L, Liu XY, et al. A chemical screen identifies PRMT5 as a therapeutic vulnerability for paclitaxel-resistant triple-negative breast cancer. Cell Chem Biol. 2024;31:1942\u201357.e6.","journal-title":"Cell Chem Biol"},{"key":"1713_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116887","volume":"279","author":"JW Wu","year":"2024","unstructured":"Wu JW, Li DP, Wang LF. Overview of PRMT1 modulators: inhibitors and degraders. Eur J Med Chem. 2024;279:116887.","journal-title":"Eur J Med Chem"},{"key":"1713_CR50","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","volume":"1-2","author":"MJ Abraham","year":"2015","unstructured":"Abraham MJ, Murtola T, Schulz R, P\u00e1ll S, Smith JC, Hess B, et al. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 2015;1-2:19\u201325.","journal-title":"SoftwareX"},{"key":"1713_CR51","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/wcms.81","volume":"2","author":"F Neese","year":"2012","unstructured":"Neese F. The ORCA program system. Wires Comput Mol Sci. 2012;2:73\u201378.","journal-title":"Wires Comput Mol Sci"},{"key":"1713_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/wcms.1606","volume":"12","author":"F Neese","year":"2022","unstructured":"Neese F. Software update: the ORCA program system-version 5.0. Wires Comput Mol Sci. 2022;12:1\u201315.","journal-title":"Wires Comput Mol Sci"},{"key":"1713_CR53","unstructured":"Lu T. Sobtop (Version 1.0 dec5). http:\/\/sobereva.com\/soft\/Sobtop. Accessed 16 Oct 2024."},{"key":"1713_CR54","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","volume":"11","author":"JA Maier","year":"2015","unstructured":"Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Simmerling C. ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB. J Chem Theory Comput. 2015;11:3696\u2013713.","journal-title":"J Chem Theory Comput"},{"key":"1713_CR55","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/08927028808080941","volume":"1","author":"WF Van Gunsteren","year":"1988","unstructured":"Van Gunsteren WF, Berendsen HJC. A leap-frog algorithm for stochastic dynamics. Mol Simula. 1988;1:173\u201385.","journal-title":"Mol Simula"},{"key":"1713_CR56","doi-asserted-by":"publisher","first-page":"8577","DOI":"10.1063\/1.470117","volume":"103","author":"U Essmann","year":"1995","unstructured":"Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, Pedersen LG. A smooth particle mesh Ewald method. J Chem Phys. 1995;103:8577\u201393.","journal-title":"J Chem Phys"},{"key":"1713_CR57","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H","volume":"18","author":"B Hess","year":"1997","unstructured":"Hess B, Bekker H, Berendsen HJC, Fraaije JGEM. LINCS: a linear constraint solver for molecular simulations. J Comput Chem. 1997;18:1463\u201372.","journal-title":"J Comput Chem"},{"key":"1713_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52507-y","volume":"15","author":"J Walton","year":"2024","unstructured":"Walton J, Ng ASN, Arevalo K, Apostoli A, Meens J, Karamboulas C, et al. PRMT1 inhibition perturbs RNA metabolism and induces DNA damage in clear cell renal cell carcinoma. Nat Commun. 2024;15:8232.","journal-title":"Nat Commun"},{"key":"1713_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.118123","volume":"300","author":"QS Zhang","year":"2025","unstructured":"Zhang QS, Zhou SY, Chen XY, Yu LT, Zhou XL. Discovery of novel indazole derivatives as type \u2160 PRMTs inhibitors for the treatment of triple-negative breast cancer. Eur J Med Chem. 2025;300:118123.","journal-title":"Eur J Med Chem"},{"key":"1713_CR60","doi-asserted-by":"publisher","first-page":"45427","DOI":"10.1021\/acsami.9b16323","volume":"11","author":"MJ Gu","year":"2019","unstructured":"Gu MJ, Toh TB, Hooi L, Lim JJ, Zhang XY, Chow EKH. Nanodiamond-mediated delivery of a G9a inhibitor for hepatocellular carcinoma therapy. ACS Appl Mater Interfaces. 2019;11:45427\u201341.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1713_CR61","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.ccell.2020.04.014","volume":"37","author":"ZT Wang","year":"2020","unstructured":"Wang ZT, Hausmann S, Lyu R, Li TM, Lofgren SM, Flores NM, et al. SETD5-coordinated chromatin reprogramming regulates adaptive resistance to targeted pancreatic cancer therapy. Cancer Cell. 2020;37:834\u2013849.e13.","journal-title":"Cancer Cell"},{"key":"1713_CR62","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/s41580-022-00483-w","volume":"23","author":"J Padeken","year":"2022","unstructured":"Padeken J, Methot SP, Gasser SM. Establishment of H3K9-methylated heterochromatin and its functions in tissue differentiation and maintenance. Nat Rev Mol Cell Biol. 2022;23:623\u201340.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1713_CR63","doi-asserted-by":"publisher","first-page":"6873","DOI":"10.7150\/thno.49235","volume":"11","author":"X Li","year":"2021","unstructured":"Li X, Gera L, Zhang S, Chen Y, Lou L, Wilson LM, et al. Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer. Theranostics. 2021;11:6873\u201390.","journal-title":"Theranostics"},{"key":"1713_CR64","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.apsb.2023.11.012","volume":"14","author":"XX Zhong","year":"2024","unstructured":"Zhong XX, Wei X, Xu Y, Zhu XH, Huo B, Guo X, et al. The lysine methyltransferase SMYD2 facilitates neointimal hyperplasia by regulating the HDAC3\u2013SRF axis. Acta Pharm Sin B. 2024;14:712\u201328.","journal-title":"Acta Pharm Sin B"},{"key":"1713_CR65","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s41422-020-0281-1","volume":"30","author":"Y Chen","year":"2020","unstructured":"Chen Y, Lyu RT, Rong BW, Zheng YX, Lin Z, Dai RF, et al. Refined spatial temporal epigenomic profiling reveals intrinsic connection between PRDM9-mediated H3K4me3 and the fate of double-stranded breaks. Cell Res. 2020;30:256\u201368.","journal-title":"Cell Res"},{"key":"1713_CR66","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1093\/cvr\/cvac148","volume":"118","author":"D Torella","year":"2023","unstructured":"Torella D, Salerno N, Cianflone E. SETD7 methyltransferase is a key druggable target for effective cardioprotection from myocardial ischaemic injury. Cardiovasc Res. 2023;118:3269\u201371.","journal-title":"Cardiovasc Res"},{"key":"1713_CR67","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.cell.2017.07.043","volume":"170","author":"S Hamperl","year":"2017","unstructured":"Hamperl S, Bocek MJ, Saldivar JC, Swigut T, Cimprich KA. Transcription-replication conflict orientation modulates R-loop levels and activates distinct DNA damage responses. Cell. 2017;170:774\u2013786.e19.","journal-title":"Cell"},{"key":"1713_CR68","doi-asserted-by":"publisher","first-page":"6763","DOI":"10.1007\/s00018-021-03926-3","volume":"78","author":"K Yoshida","year":"2021","unstructured":"Yoshida K, Fujita M. DNA damage responses that enhance resilience to replication stress. Cell Mol Life Sci. 2021;78:6763\u201373.","journal-title":"Cell Mol Life Sci"},{"key":"1713_CR69","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41580-019-0190-7","volume":"21","author":"J Luo","year":"2020","unstructured":"Luo J, Yang HY, Song BL. Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol. 2020;21:225\u201345.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1713_CR70","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1042\/CS20220752","volume":"137","author":"CC Bao","year":"2023","unstructured":"Bao CC, Wu T, Zhu SY, Wang XY, Zhang YJ, Wang XX, et al. Regulation of cholesterol homeostasis in osteoporosis mechanisms and therapeutics. Clin Sci. 2023;137:1131\u201343.","journal-title":"Clin Sci"},{"key":"1713_CR71","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41392-022-01125-5","volume":"7","author":"YJ Duan","year":"2022","unstructured":"Duan YJ, Gong K, Xu SW, Zhang F, Meng XS, Han JH. Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. Signal Transduct Target Ther. 2022;7:265.","journal-title":"Signal Transduct Target Ther"},{"key":"1713_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2021.100754","volume":"55","author":"T Das","year":"2021","unstructured":"Das T, Anand U, Pandey SK, Ashby CR Jr., Assaraf YG, Chen ZS, et al. Therapeutic strategies to overcome taxane resistance in cancer. Drug Resist Updat. 2021;55:100754.","journal-title":"Drug Resist Updat"},{"key":"1713_CR73","doi-asserted-by":"crossref","unstructured":"Zhang Y, Xu Q, Tian X, Xia X, Chen S, Liu F, et al. Longitudinal changes in remnant cholesterol and the risk of cardiovascular disease. Cardiovasc Diabetol. 2025;24:1.","DOI":"10.1186\/s12933-024-02556-w"},{"key":"1713_CR74","doi-asserted-by":"publisher","first-page":"265","DOI":"10.7150\/thno.27246","volume":"9","author":"H Jin","year":"2019","unstructured":"Jin H, He Y, Zhao P, Hu Y, Tao J, Chen J, et al. Targeting lipid metabolism to overcome EMT-associated drug resistance via integrin beta3\/FAK pathway and tumor-associated macrophage repolarization using legumain-activatable delivery. Theranostics. 2019;9:265\u201378.","journal-title":"Theranostics"},{"key":"1713_CR75","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.cmet.2025.04.014","volume":"37","author":"JP Rose","year":"2025","unstructured":"Rose JP, Morgan DA, Sullivan A, Fu XR, Inigo-Vollmer M, Burgess SC, et al. FGF21 reverses MASH through coordinated actions on the CNS and liver. Cell Metab. 2025;37:1515\u20131529.e6.","journal-title":"Cell Metab"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01713-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01713-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01713-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T10:02:47Z","timestamp":1777024967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01713-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":75,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1713"],"URL":"https:\/\/doi.org\/10.1038\/s41401-025-01713-5","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"22 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}